Doxylid

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Doxylid

What is Doxylid?

Doxylid is a pharmaceutical formulation containing the active substance doxycycline, which belongs to a class of medications known as tetracycline antibiotics. It is primarily utilized for its ability to inhibit the growth of various types of bacteria and certain other microorganisms.

Mechanism of Action

Doxylid works by interfering with the protein synthesis of bacteria. By binding to specific subunits within the bacterial ribosome, it prevents the addition of amino acids to the growing peptide chain. This action stops the bacteria from multiplying and spreading, allowing the body's natural immune system to manage the remaining infection.

Therapeutic Applications

This medication is characterized by its broad-spectrum activity, meaning it is effective against a wide range of Gram-positive and Gram-negative bacteria. It is commonly used in the management of:

  • Respiratory Tract Infections: Including certain types of pneumonia and chronic bronchitis.
  • Urinary Tract Infections: Caused by susceptible strains of bacteria.
  • Skin and Soft Tissue Infections: Such as severe acne or specialized skin conditions.
  • Vector-borne Diseases: Including certain infections transmitted by ticks, lice, or mites, such as Rocky Mountain spotted fever or Lyme disease.
  • Ocular Infections: Specific bacterial infections affecting the eyes.

Beyond its antibacterial properties, Doxylid is sometimes utilized for its anti-inflammatory effects in chronic conditions or as a preventative measure in specific travel-related scenarios, such as the prevention of malaria in certain geographical regions.

Regulatory References

  1. Doxorubicin - StatPearls - NCBI Bookshelf
  2. Doxorubicin Hydrochloride - NCI - National Cancer Institute
  3. Definition of doxorubicin hydrochloride - NCI Dictionary of Cancer Terms
  4. Myocet liposomal (previously Myocet) | European Medicines Agency (EMA)

What side effects are possible with Doxylid?

Possible Side Effects and Safety Information

The safety profile for Doxylid (Doxorubicin) is established through official regulatory documentation, which classifies adverse reactions by frequency and affected body system. A primary safety concern highlighted by regulatory bodies is dose-limiting organ toxicity.

Adverse Reaction Classification

The most frequent acute side effects are classified as Very Common (ge 1/10) and include Myelosuppression (a decrease in blood cell counts, such as leukopenia and neutropenia), gastrointestinal reactions like stomatitis (inflammation of the mouth) and nausea/vomiting, and total alopecia (hair loss). Reactions classified as Common (ge 1/100 to <1/10) include Congestive Cardiac Failure and the risk of developing secondary malignancies (e.g., AML).

Serious Adverse Reactions and Safety Constraints

Official labeling emphasizes the risk of Cardiomyopathy (heart muscle damage) which can be severe and is strictly related to the total cumulative dose received over a lifetime; cardiac events can be delayed, appearing months or years after therapy. Use is restricted in patients with severe hepatic impairment or pre-existing severe myocardial insufficiency. Furthermore, local administration carries a risk of severe extravasation (tissue injury if the drug leaks outside the vein).

Population-specific safety considerations state that pediatric patients face an increased long-term risk for delayed cardiotoxicity.

System-Organ Classes Affected

Side effects are officially documented across several systems, notably Cardiac Disorders, Blood and Lymphatic System Disorders, Gastrointestinal Disorders, and Skin and Subcutaneous Tissue Disorders (e.g., Palmar-plantar erythrodysesthesia).

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes Doxylid (Doxorubicin) overdose as an acute exaggeration of its dose-dependent toxic effects, requiring immediate medical intervention.


Documented Overdose Manifestations

Severe overdose presentations are documented to include life-threatening complications. Clinical signs noted in regulatory sources are consistent with: Severe Myelosuppression, leading to fever, chills, and unusual bleeding; Severe Stomatitis and Gastrointestinal Hemorrhage, manifesting as bloody vomit or black, tarry stools; and acute cardiac toxicity, potentially causing Acute Left Ventricular Failure.

Required Emergency Actions

The prescribing information and national health agencies explicitly mandate urgent action when overdose is suspected. Immediate medical help must be sought for all signs of overdose. Life-threatening events—specifically seizure, inability to be awakened, or severe trouble breathing—require calling emergency services (911) immediately.


Management and Considerations

No specific antidote is known for systemic Doxylid overdose, meaning management is strictly limited to supportive and symptomatic treatment, including procedures like transfusions, as necessitated by myelosuppression. The regulatory text advises on procedural steps for severe local injury, requiring the immediate termination of the infusion upon suspicion of extravasation. Furthermore, pediatric patients are officially noted to have an increased risk of developing delayed cardiotoxicity following high cumulative drug exposure.

Therapeutic Uses of Doxylid

Main Uses of Doxylid

Doxylid is a broad-spectrum antibiotic belonging to the tetracycline class. It is primarily used to treat a variety of bacterial infections by inhibiting the growth and spread of bacteria within the body.

Respiratory Tract Infections

Doxylid is frequently utilized to manage infections of the respiratory system. This includes conditions such as pneumonia, chronic bronchitis exacerbations, and sinusitis. It is effective against several common pathogens that affect the lungs and airways.

Urinary Tract and Genital Infections

The medication is indicated for the treatment of certain infections of the urinary tract. It is also a standard option for various sexually transmitted infections, including chlamydia and non-gonococcal urethritis.

Skin and Soft Tissue Infections

Certain inflammatory skin conditions and bacterial infections of the skin may be treated with Doxylid. It is often prescribed for the management of severe acne when topical treatments have proven insufficient.

Vector-Borne Diseases

Doxylid plays a critical role in treating diseases transmitted by ticks, fleas, or lice. These include:

  • Lyme disease
  • Rocky Mountain spotted fever
  • Relapsing fever

Prevention of Specific Conditions

In addition to treating active infections, Doxylid may be used as a prophylactic measure. This is most common for the prevention of malaria in individuals traveling to areas where the disease is prevalent and resistant to other medications.

Benefits of Doxylid Therapy

  • Broad Spectrum Activity: It is effective against a wide range of both Gram-positive and Gram-negative bacteria.
  • Tissue Penetration: The medication is known for its ability to penetrate deeply into various body tissues and fluids, making it effective for localized infections.
  • Alternative for Penicillin-Allergic Patients: For individuals who are allergic to penicillin-type antibiotics, Doxylid often serves as an essential alternative for treating common bacterial ailments.

Regulatory References

  1. NIH StatPearls overview on Anthracycline Medications (Doxorubicin)

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Doxylid (Doxorubicin) — Official Regulatory Information

Category Official Regulatory Statement
Populations for whom use is allowed Adult and Pediatric patients with certain malignancies who have sufficient cardiac, hepatic, and hematologic function.
Populations for whom use is contraindicated Patients who have reached the maximum lifetime cumulative dose of Doxorubicin (typically 550 mg/m^2 or lower with risk factors). Patients with severe hepatic impairment (bilirubin >5 mg/dL or equivalent). Patients with severe myocardial insufficiency, recent myocardial infarction (within 4–6 weeks), or severe arrhythmias. Patients with persistent myelosuppression or generalized infection.
Age-related eligibility rules Pediatric patients are eligible for use but require long-term cardiac monitoring due to increased risk for delayed cardiotoxicity. Older adults may require a lower dose if they have inadequate marrow reserves.
Condition-specific eligibility rules Impaired Hepatic Function: Mandatory dose reduction is required for patients with elevated serum total bilirubin (1.2 to 5 mg/dL), but it is contraindicated if bilirubin is higher. Renal Impairment: Patients with severe insufficiency may require a dose adjustment.
Pregnancy and lactation eligibility status Pregnancy is contraindicated (classified as Category D, posing a potential risk of fetal harm). Lactation is contraindicated as the drug is secreted into human milk. Females of reproductive potential must use effective contraception.

Official Eligibility Statements:

  • The medicine is contraindicated in patients who have received the maximum lifetime dose of Doxorubicin or other anthracyclines, which is a major eligibility constraint.
  • Severe cardiac disorders and severe hepatic impairment are also absolute contraindications for use.
  • Eligibility for all patients is conditional upon monitoring for Left Ventricular Ejection Fraction (LVEF), and treatment must be discontinued upon a significant decline in cardiac function.

Connection to the Overall Eligibility Profile:

Official regulatory documents define Doxylid eligibility primarily through clear exclusions centered on cumulative exposure and organ function to mitigate the risk of irreversible cardiotoxicity. The absolute maximum lifetime dose and pre-existing severe hepatic or cardiac dysfunction establish non-eligible patient groups. All other populations, including pediatric patients, require conditional use based on organ-function status and strict cardiac monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation details the specific substances and conditions that may alter the exposure or safety profile of Doxylid (Doxorubicin).

Pharmacokinetic and Exposure-Altering Interactions

The co-administration of Doxylid with strong inhibitors of CYP3A4, CYP2D6, or P-glycoprotein (P-gp) may increase the systemic exposure (plasma concentrations) of Doxylid. Conversely, co-administration with strong inducers of these same enzymes and the P-gp transporter may decrease exposure.

Pharmacodynamic and Toxicity Reinforcement

  • Cardiotoxic Agents: Using Doxylid concurrently with Trastuzumab or other cardiotoxic agents, including other anthracyclines, increases the risk of cardiac dysfunction.
  • Toxicity Potentiation: Co-administration with other DNA-damaging anti-neoplastic agents or radiotherapy increases the documented risk of developing secondary leukemias. Doxylid may also potentiate the hepatotoxicity caused by 6-mercaptopurine.

Administrative Constraints and Timing

  • Timing Rule: Doxylid must be administered prior to Paclitaxel when used concomitantly. Administering Paclitaxel first is documented to increase Doxylid's plasma concentrations.
  • Physical Incompatibility: Doxylid is physically and chemically incompatible with both Heparin and Fluorouracil; these agents should not be mixed with Doxylid solution due to the risk of precipitation.
  • Food Interaction: Ingestion of Grapefruit or Grapefruit Juice is officially noted to interfere with the drug’s breakdown, potentially leading to higher systemic levels.

Mechanism of Action

Dual Mechanism: Disrupting DNA Function and Cell Cycle

Doxylid exerts its core action by physically inserting itself into the DNA double helix (intercalation) and simultaneously disabling the enzyme Topoisomerase II (TOP2), which is crucial for managing DNA structure. This genetic blueprint interference introduces catastrophic, unrepairable DNA damage that triggers the DNA Damage Response (DDR), forcing the target cell to halt its division cycle.

Generating Intracellular Oxidative Stress

The drug also contributes to cell destruction through a unique chemical process called redox cycling, primarily occurring in the cell's mitochondria. This cascade rapidly generates high levels of Reactive Oxygen Species (ROS), which cause immediate and systemic damage to the cell's internal structures, including lipids and proteins. This dual molecular assault, combining genetic interference with oxidative stress, ensures the physiological outcome of widespread programmed cell death (apoptosis), reducing the target cell population.

Constraints on Molecular Specificity

The overall mechanistic effect is constrained by two key limitations: active expulsion of the drug from the cell via efflux pumps (reducing the effective intracellular concentration), and the drug's non-selective inhibition of the TOP2 beta isoform, which causes off-target molecular activity in quiescent cells.

Dosage and Administration Information

Administration Overview

Doxylid is an oral medication intended for systemic use. Proper administration is essential to ensure the stability of the active ingredient and to facilitate its absorption within the digestive tract.

General Method of Use

The tablets are typically swallowed whole with a sufficient volume of water. To minimize the potential for irritation in the esophagus or stomach, it is often recommended to take the medication while in an upright position (sitting or standing) rather than while lying down. Maintaining an upright posture for a period after administration can also assist in the transit of the medication to the stomach.

Considerations for Intake

  • Consistency: Taking the medication at the same time each day helps maintain steady levels of the substance in the body.
  • Food Interaction: Depending on the specific formulation, the presence of food may or may not impact the absorption rate. Generally, the medication can be taken with or without food, though a consistent routine is advised.
  • Hydration: Adequate fluid intake during administration is a standard practice to support the delivery of the medication.

Handling and Storage

To maintain the integrity of the medication, tablets should be kept in their original packaging until the time of use. This protects the contents from environmental factors such as light and moisture, which can affect the chemical stability of the product. Store the medication in a cool, dry place away from direct heat.

Recent Clinical Evidence

Research evidence / Overview of studies for Doxylid

Evidence for Use in Advanced and Metastatic Solid Tumors

This section will summarize the types of high-level clinical trials and systematic reviews that have examined Doxylid in the treatment frameworks for cancers such as breast cancer, ovarian carcinoma, and soft tissue sarcomas. The focus is on the design and measurable end-points of the available research, such as tumor response and survival tracking.

Research for Doxylid in the treatment of various advanced solid tumors was studied for its role in Randomized Controlled Trials (RCTs). These studies compared treatment regimens that included Doxylid against non-anthracycline regimens or other chemotherapy combinations in adult patients. Researchers generally examined monitoring key measurements such as Overall Survival (OS) and Progression-Free Survival (PFS). Studies also monitored the Objective Response Rate (ORR), which tracks tumor size measurements.

Analyses of the specific populations reported measurements related to survival time in studies of conditions like metastatic breast cancer and soft tissue sarcomas. Systematic reviews, which combine data from multiple RCTs, contribute to the broader evidence landscape by synthesizing outcomes related to the use of Doxylid as a core component of established treatment plans. Doxylid was studied for its inclusion as an agent in many established combination protocols, but certain long-term effects of treatment, such as cardiovascular outcomes, require follow-up periods that can span decades to fully characterize.

Evidence for Use in Hematologic Malignancies and Lymphomas

This part will describe the large-scale cooperative group trials and analyses that position Doxylid as a component of multi-agent chemotherapy regimens for conditions like Hodgkin Lymphoma and Acute Lymphoblastic Leukemia. The summary will focus on the structure of evidence regarding event-free survival and remission measurements in these specific blood cancers.

Doxylid was evaluated in large-scale cooperative group clinical trials for various blood cancers. These trials primarily examined the agent as part of complex, multi-drug protocols and included both adult and pediatric populations. Key outcomes monitored were Event-Free Survival (EFS), Overall Survival (OS), and the rate at which patients achieved a Complete Remission (CR).

The Evidence Landscape: Uncertainty and Research Gaps

This concluding section will synthesize the major limitations noted within the scientific literature, such as small sample sizes in certain groups, heterogeneity across older trials, and areas where regulatory or peer-reviewed bodies indicate that more research is needed to refine the existing understanding.

Overall, the research for Doxylid provides a substantial body of evidence but also has clear limitations. Sample sizes were modest in studies for rare cancers, making those subgroup findings uncertain. For many adult cancers, evidence quality varies because trials conducted decades ago often used comparator regimens that are no longer standard today. A primary research gap is the need for more information on how to optimize dose intensity and administration, particularly as it relates to long-term monitoring in all patient groups, including heart function. Furthermore, the results apply only to the populations studied, and there is limited information regarding outcomes for individuals with certain pre-existing health conditions who were generally excluded from the original clinical trials.

Frequently Asked Questions (FAQ)

Common questions about Doxylid (FAQ)

Q: Why do some people refer to Doxylid as a 'broad-spectrum' drug?

Doxylid belongs to a class of medicines known as anthracyclines, which are utilized in systemic chemotherapy. Official descriptions highlight its broad applicability, noting that it is used to target rapidly dividing malignant cells across numerous tumor types.


Q: Is Doxylid taken long-term or short-term?

This medicine is administered in specific, repeating treatment cycles, which typically last 21 or 28 days. Official documentation notes a maximum cumulative lifetime dose that may be received.


Q: Can certain vitamins or supplements affect how Doxylid works?

Official documents caution against using Doxylid concurrently with strong inhibitors or inducers of certain enzymes that process the drug, as these can affect how Doxylid works in the body. Regulatory documents focus primarily on prescription drug interactions, although specific supplements may carry theoretical risks for metabolism or safety.


Q: What types of foods or drinks should people be aware of while taking Doxylid?

Official documents contain a specific warning regarding certain beverages. The ingestion of Grapefruit or Grapefruit Juice may interfere with the body's breakdown of Doxylid, potentially leading to higher systemic levels.


Q: Is Doxylid generally considered appropriate for elderly patients?

Official documents state that older adults may be eligible for treatment. However, they may require a lower dose or longer administration intervals if they have inadequate marrow reserves. These considerations are incorporated into the treatment plan.


Q: Are there special considerations for taking Doxylid if a person has kidney issues?

For patients with severe kidney insufficiency, regulatory information states that a dose adjustment may be required. Regulatory information notes that the medicine has the potential to affect kidney function.


Q: What are the different strengths or forms of Doxylid available?

Doxylid is manufactured for delivery by healthcare professionals. It is supplied as a sterile solution for injection or a powder that is mixed with fluid for reconstitution before administration. The specific drug strengths available are defined in the official prescribing information.


Q: How is the action of Doxylid different from standard remedies for the same symptoms?

The medicine’s core action involves a dual assault on target cells. Its dual action involves physically damaging the cell’s genetic material (DNA) while also generating certain harmful molecules inside the cell. This dual mechanism is designed to disrupt the cell's structure and division process.


Q: Is it normal to feel a mild burning sensation when taking Doxylid?

A burning or stinging sensation felt during infusion is an important sign of a potential issue called extravasation. This is where the drug leaks outside the vein. If this occurs, procedures require the healthcare professional to immediately stop the infusion.


Q: Do the side effects of Doxylid usually disappear after a few days?

The duration of side effects varies widely. For instance, temporary blood count decreases (myelosuppression) usually reach their lowest point after 10–14 days, and hair regrowth typically begins a few months after treatment is finished.


Q: What is the official safety classification of Doxylid?

Official documentation classifies Doxylid as a hazardous and cytotoxic (toxic to cells) drug. Regulatory bodies also classify it based on reproductive risk, noting it as Pregnancy Category D.


Q: Does taking Doxylid require any specific dietary adjustments?

Official regulatory documents note a specific interaction with Grapefruit and Grapefruit Juice. No other general dietary adjustments are typically required based on this specific official warning.


Q: What information is publicly available about the active ingredient in Doxylid?

Publicly available regulatory information confirms that the active ingredient is Doxorubicin. This compound is classified as an anthracycline antineoplastic agent used in systemic chemotherapy.


Q: Is Doxylid generally well-tolerated by most people?

Official documentation indicates that many patients experience adverse reactions. Very common acute side effects, which affect more than one out of ten people, include myelosuppression (blood cell decrease), nausea/vomiting, and total hair loss.


Q: What does current research indicate about the long-term use of Doxylid?

Long-term follow-up and monitoring are required, particularly for pediatric patients, as there is a documented risk of delayed cardiotoxicity (heart damage) that may manifest months or years after treatment.


Q: Is Doxylid related to other medications whose names sound similar?

Yes, the active ingredient Doxorubicin belongs to the larger pharmacological class of anthracyclines. This class includes other related medicines, leading to similar-sounding names.


Q: What should a patient do if they miss a dose of Doxylid?

The administration of Doxylid is managed via a precise, standardized cyclic schedule by healthcare professionals. Any specific guidance regarding a missed dose must be determined by the prescribing healthcare team.


Q: Are there any reported side effects of Doxylid on sleep patterns?

While explicit sleep disturbance is not always directly listed in official documents, common adverse reactions such as fatigue (extreme tiredness) and asthenia (weakness) are reported. These conditions can impact a patient’s general rest and activity levels.


Q: Does Doxylid commonly cause sensitivity to sunlight?

Yes, regulatory-related documents have reported photosensitivity as a possible dermatological side effect. This means the skin may have an unusual sensitivity to sunlight.


Q: Is a headache a frequently reported side effect of Doxylid?

Headache has been noted in official reports as one of the acute reactions that can occur during the drug infusion. In studies of a related formulation, headache was reported in up to 10% of patients.


Q: Does Doxylid interact with common pain relief medicines like ibuprofen?

Official guidance focuses on avoiding co-administration with inhibitors and inducers of specific enzymes (CYP/P-gp) that help the body process the drug. These categories include specific classes of medicines, potentially including certain pain relief drugs.


Q: What happens if Doxylid is stopped suddenly?

Treatment cessation is strictly managed by a healthcare professional. The decision to stop Doxylid is conditional upon ongoing monitoring for significant safety events, such as a severe decline in cardiac function or dose-limiting toxicity.


Q: Why might a doctor prescribe Doxylid instead of a different medication?

Doxylid is an established agent in the anthracycline class, positioned as a key component of systemic chemotherapy for many cancers. It is prescribed because it plays a defined role in evidence-based combination protocols for various cancer types.


Q: Is there an official patient leaflet or information sheet for Doxylid?

Yes, official regulatory documents reference patient information resources. These include FDA-approved patient labeling and patient counseling information provided to the individual receiving the drug.


Q: Are there different brand names for the medicine Doxylid?

Yes, the active ingredient Doxorubicin hydrochloride is the basis for multiple brand names recognized and used within the field of oncology.


Q: Can Doxylid affect blood sugar levels?

While this is not always listed as a common side effect, research, including laboratory studies, has explored the drug’s potential to affect the body's metabolism, noting changes related to blood sugar and insulin resistance.


Q: Are there potential issues if Doxylid is taken at the same time as a calcium supplement?

Official guidance is centered on avoiding co-administration with strong inhibitors/inducers of specific enzymes. Separately, the drug has been noted in some literature to interact with certain calcium channel blockers.


Q: How long does Doxylid stay in the body after the last intake?

Studies on the drug's elimination indicate that it has a terminal half-life that can range from 35 to 54 hours. The excretion of the medicine from the body can continue for several days following administration.


Q: Is it true that Doxylid can cause discoloration of teeth?

Discoloration of the teeth is not typically noted in official documents. However, pigmentation changes in other areas, such as the darkening of the nail beds, soles of the feet, or palms, have been reported.


Q: What is the meaning of the specific warning box (Black Box Warning) associated with Doxylid, if any?

The FDA requires a Boxed Warning to draw attention to the most serious safety concerns associated with the medicine. This warning highlights the risks of severe heart damage (cardiomyopathy), secondary cancers, extravasation (leakage) and tissue death, and severe blood cell decrease (myelosuppression).

How should Doxylid be stored and disposed of?

Doxylid (Doxorubicin Hydrochloride) is a cytotoxic injection requiring strict adherence to regulatory storage and disposal protocols.

Required Storage Conditions

  • The liquid injection solution must be stored under refrigerated conditions between 2°C to 8°C (36°F to 46°F).
  • The vials must be protected from light and kept in the original carton.
  • The medicine must be kept out of the reach and sight of children.
  • The final diluted infusion solution must be used within one hour of preparation.

Disposal and Handling

  • Doxylid is classified as a hazardous/cytotoxic drug and must be disposed of according to special regulatory procedures.
  • The product, including any unused portion from single-dose vials, must not be placed in household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Doxylid found in:

A-Z Index: